首页> Journal for immunotherapy of cancer> Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.

导出 LinkOut

翻译打印收藏纠错

第一作者： Rim,Trad

第一单位： TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.

作者： Rim,Trad ^[1] ; Walid,Warda ^[2] ; Vincent,Alcazer ^[3] ; Mathieu,Neto da Rocha ^[2] ; Ana,Berceanu ^[4] ; Clémentine,Nicod ^[1] ; Rafik,Haderbache ^[1] ; Xavier,Roussel ^[4] ; Yohan,Desbrosses ^[4] ; Etienne,Daguindau ^[4] ; Florain,Renosi ^[1] ; Christophe,Roumier ^[5] ; Lucie,Bouquet ^[1] ; Sabeha,Biichle ^[1] ; Melanie,Guiot ^[1] ; Evan,Seffar ^[1] ; Denis,Caillot ^[6] ; Stephane,Depil ^[7] ; Eric,Robinet ^[8] ; Yahya,Salma ^[9] ; Eric,Deconinck ^[4] ; Marina,Deschamps ^[2] ; Christophe,Ferrand ^[10]

作者单位： TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France. ^[1] TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.;CanCell Therapeutics, Besancon, France. ^[2] Clinical Hemaology, C.H. Lyon Sud, Lyon, France. ^[3] Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France. ^[4] Hematology Lab, CHU Lille, Lille, France. ^[5] Clinical Hematology, CHU François Mitterrand, Dijon, France. ^[6] Clinical Hematology, C.H. Lyon Sud, Lyon, France. ^[7] Lymphobank SAS, Besancon, France. ^[8] Laboratory of Applied Biotechnology (LBA3B), Lebanese University, Tripoli, Lebanon. ^[9] TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France christophe.ferrand@efs.sante.fr.;CanCell Therapeutics, Besancon, France. ^[10]

关键词 T-lymphocytes cytotoxicity, immunologic hematologic neoplasms immunotherapy